{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-007013","form_type":"8-K","ticker":"XAIR","cik":"0001641631","company_name":"Beyond Air, Inc.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.948585+00:00","generated_at":"2026-06-06T00:15:20.831175+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Beyond Air Q3 FY2024 net loss $16.2M; revenues $0.4M; FY2025 guidance reiterated $12-16M","bullets":["Net loss $16.2M ($0.50 per share) vs $12.7M ($0.43) in Q3 FY2023; revenues $0.4M from zero prior year.","FY2025 revenue guidance reiterated at $12M-$16M; LungFit PH filter shipments up >100% QoQ.","PMA supplement for cardiac surgery label expansion accepted for filing and under FDA substantive review.","Cash, marketable securities $31.4M as of Dec 31, 2023; raised $5.5M via ATM to offset burn.","CMO Dr. Myers transitions to consultant effective Feb 16; CCO Duncan Fatkin leaves March 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-007013","json":"https://secwatch.observer/filing/0001493152-24-007013.json","markdown":"https://secwatch.observer/filing/0001493152-24-007013.md","text":"https://secwatch.observer/filing/0001493152-24-007013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641631/000149315224007013/0001493152-24-007013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641631/000149315224007013/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:15:20.831175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d7d17fdfd75f2fb29eef4c7e2569bf508c7f5c0","claim":"Beyond Air, Inc. reported third quarter of fiscal year 2024 (fiscal quarter ended December 31, 2023) results: revenue $0.4 million, net income ($16.2) million, EPS ($0.50) per share, basic and diluted. Guidance reaffirmed.","evidence_excerpt":"and will provide updates as appropriate 2 Financial Results for the Fiscal Quarter Ended December 31, 2023 Revenues for the three months ended December 31, 2023 were $0.4 million compared to zero for the quarter ended December 31, 2022. Cost of revenue of $0.7 million was recognized for the three months ended December 31, 2023, compared to $0.1 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641631/000149315224007013/0001493152-24-007013-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of fiscal year 2024 (fiscal quarter ended December 31, 2023)"},{"label":"Revenue","value":"$0.4 million"},{"label":"Net income","value":"($16.2) million"},{"label":"EPS","value":"($0.50) per share, basic and diluted"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}